The hypertrophic cardiomyopathy (hcm) therapeutics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown steadily in recent years. It will grow from $1.3 billion in 2023 to $1.34 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding.
The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.48 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%. The growth in the forecast period can be attributed to genetic research and personalized medicine, emerging therapeutic modalities, collaborative research initiatives, patient-centric healthcare models, lobal health initiatives. Major trends in the forecast period include advancements in targeted therapies, personalized medicine and genetic testing:, drug pipeline expansion, collaborations and partnerships, patient-centric approaches.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/hypertrophic-cardiomyopathy-hcm-therapeutics-global-market-report
Scope Of Hypertrophic Cardiomyopathy (HCM) Therapeutics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview
Market Drivers –
The increasing incidence of cardiovascular diseases (CVD) is expected to propel the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular disease (CVD) is a condition that affects the heart or blood vessels. Cardiovascular diseases include heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block that require long-term monitoring. The primary need for therapeutics treatment for hypertrophic cardiomyopathy aims to alleviate symptoms and avoid sudden cardiac death in high-risk patients. For instance, according to the October 2022 report of the Center For Disease Control and Prevention (CDCP), a US-based national public health agency, in the United States, one person dies from cardiovascular disease every 36 seconds, and CVD is responsible for nearly 836,546 deaths in the United States alone in 2021. Therefore, the increasing incidence of cardiovascular diseases (CVD) drives the hypertrophic cardiomyopathy (HCM) therapeutics market.
Market Trends –
Product innovations are the key trend gaining popularity in the hypertrophic cardiomyopathy (HCM) therapeutics market. Major companies operating in the cardiomyopathy therapeutics sector are focused on developing new innovative products to strengthen their position in the market. For instance, in April 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, launched Camzyos (mavacamten), an oral small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of heart diastolic dysfunction. Camzyos (mavacamten) was approved by the US Food and Drug Administration (FDA) for the treatment of adults with symptomatic class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor of cardiac myosin that targets the underlying pathophysiology of obstructive HCM. Camzyos controls the number of myosin heads that can enter “on actin” (power-generating) states.
The hypertrophic cardiomyopathy (hcm) therapeutics market covered in this report is segmented –
1) By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types
2) By Device Type: Defibrillators, Pacemakers, Other Device Types
3) By End User: Hospitals, Clinics
Get an inside scoop of the hypertrophic cardiomyopathy (hcm) therapeutics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=9914&type=smp
Regional Insights –
North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Key Companies –
Major companies operating in the hypertrophic cardiomyopathy (hcm) therapeutics market report are Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Abbott Laboratories Inc., Advanz Pharma Corp., Lupin Limited, Myokardia Inc., Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Mylan N.V., Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Janssen Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited .
Table of Contents
1. Executive Summary
2. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report Structure
3. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends And Strategies
4. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market – Macro Economic Scenario
5. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size And Growth
…..
27. Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
